CagriSema: The Two-Hormone Weight-Loss Drug That Just Landed at the FDA's Door
Semaglutide meets amylin in a once-weekly combo shot — here's what the Phase 3 data actually shows.
I now have everything I need. Let me write the article.
Most weight-loss drugs work one way: they mimic a gut hormone called GLP-1 to slow digestion and quiet appetite. CagriSema is built on a different idea — what if you hit two completely separate hunger systems at the same time?
That question is now backed by Phase 3 data, an FDA filing, and a pair of papers published in the New England Journal of Medicine. Here's what you need to know.
What CagriSema Actually Is
CagriSema is a fixed-dose combination of two molecules injected once a week: semaglutide (the active ingredient in Ozempic and Wegovy) and cagrilintide, a long-acting analogue of a hormone called amylin.
You've probably heard plenty about semaglutide. Amylin is the less famous one. It's a hormone your pancreas releases alongside insulin when you eat, and it works in the brain to signal fullness and slow gastric emptying. According to a Lancet phase 2 trial on cagrilintide alone, the drug produced meaningful weight loss on its own — which made researchers curious whether stacking it with semaglutide would do something additive, or even synergistic.
The logic: GLP-1 and amylin act on different receptors in the brain's appetite centers. Hitting both at once might produce results neither could achieve alone.
What the REDEFINE Trials Found
Two large Phase 3 trials — REDEFINE 1 and REDEFINE 2 — just reported results, both published in the New England Journal of Medicine in 2025.
REDEFINE 1 enrolled adults with overweight or obesity (without type 2 diabetes). According to Applied Clinical Trials Online, the trial found that the cagrilintide–semaglutide combo delivered over 20% weight loss in the majority of participants — a benchmark that previously only bariatric surgery could reliably clear.
REDEFINE 2 focused on people with both obesity and type 2 diabetes — a population where weight loss is harder to achieve and metabolic stakes are higher. CagriSema was tested head-to-head against placebo and against semaglutide alone.
A systematic review and meta-analysis published in Indian Journal of Endocrinology and Metabolism that pooled earlier CagriSema data concluded the combination showed efficacy and safety as an anti-obesity treatment, with results exceeding either component on its own.
Clinical Trials Arena reported that CagriSema outperformed Ozempic (semaglutide alone) in Phase 3 head-to-head comparison — which is a meaningful bar, given how well semaglutide already performs.
Where It Stands Regulatorily
According to BioSpace (December 2025), Novo Nordisk filed CagriSema with the FDA for approval. That means the drug is now in the FDA review pipeline — not yet approved, not yet prescribable.
On ClinicalTrials.gov, an active Phase 3 trial (NCT05567796) is still running, comparing CagriSema against semaglutide alone, cagrilintide alone, and placebo — which will add to the evidence base the FDA will evaluate. A separate recruiting trial (NCT07564414) is testing two different doses of CagriSema versus semaglutide over roughly 83 weeks. There's even a Phase 3 pediatric trial (NCT07253285) now recruiting children and adolescents.
Side Effects — What We Know So Far
CagriSema hasn't been approved yet, so there's no FDA label to pull. But based on the trial data published in the NEJM and the earlier meta-analysis, the side effect picture looks similar to what you'd expect from semaglutide: nausea, vomiting, diarrhea, and constipation are the most commonly reported adverse events. These are consistent with the GLP-1 class as a whole.
MedlinePlus describes obesity as a disease that increases risk for many other conditions — which is the clinical context that makes even modest improvements in these side-effect profiles worth tolerating for many people.
Whether cagrilintide adds meaningfully to the GI burden compared to semaglutide alone is something the ongoing trials and the FDA review will clarify further.
What This Means for You
- CagriSema is not yet approved. It's in FDA review as of late 2025. If you're hearing buzz about it, that's real — but it's not something you can be prescribed today in the U.S.
- The dual-mechanism idea has real data behind it. Two NEJM papers and a meta-analysis all point in the same direction: hitting both the GLP-1 and amylin pathways at once appears to produce greater weight loss than either drug alone.
- More trials are still running. Different doses, longer durations, and pediatric populations are all being studied — so the full picture isn't written yet. Watch the ClinicalTrials.gov listings if you want to follow the data as it comes in.
Not medical advice. Talk to your prescriber about your situation.
